Nasus Pharma Earnings Call Transcripts
Fiscal Year 2026
-
A proprietary powder nasal drug delivery platform is advancing a lead epinephrine product for anaphylaxis, showing faster and higher absorption than EpiPen and entering phase III in late 2024. The company is well-funded through mid-2027, expanding its pipeline to other acute indications, and is receiving strong support from clinical experts.
-
The event highlighted the growing need for needle-free epinephrine, with strong clinical data showing rapid onset and high patient preference for intranasal delivery. KOLs emphasized the product's potential to expand the market and improve adherence, with a pivotal phase III study planned.
-
A proprietary powder-based intranasal platform is advancing multiple acute care therapies, led by a needle-free epinephrine product that outperforms EpiPen in speed and absorption. Phase III trials begin Q4, with NDA submission planned for mid-2027, and several pipeline products are entering the clinic this year.
-
Phase II results show NS002, an intranasal epinephrine powder, achieves therapeutic levels twice as fast as EpiPen, with 88% of subjects reaching threshold within 5 minutes and a favorable safety profile. The product is compact, needle-free, and may reduce the need for repeat dosing.
-
A proprietary powder technology enables a needle-free epinephrine product with faster absorption and superior pharmacokinetics compared to competitors. The lead product is advancing to pivotal trials, with a robust pipeline and significant market expansion potential in the growing anaphylaxis segment.
-
A proprietary powder-based intranasal technology is enabling rapid, needle-free drug delivery, with the lead epinephrine product showing superior absorption and safety versus EpiPen. The company is advancing a robust pipeline, fully funded through 2027, and is well positioned for growth as the market shifts toward needle-free solutions.